Slides - Clinical Trial Results .org

More documents

Recommendations

Info

Results: ITT Cohort Subgroups of Clinical Interest for Cardiac Arrest or Hospital Mortality ITT Subgroup Odds Ratio (95% CI) P Value All 0.48 (0.27-0.85) 0.01 Age: < 65 years 0.52 (0.22-1.21) Age: ≥ 65 years 0.43 (0.20-0.94) 0.13 0.04 Time from symptom onset to study drug start 0 - 1 hour 0.28 (0.10-0.79) > 1 hour - 6 hours 0.39 (0.13-1.25) > 6 hours 1.18 (0.34-4.06) 0.02 0.11 0.79 Diabetic 0.31 (0.10-0.99) Not Diabetic 0.56 (0.29-1.09) 0.05 0.09 STEMI, Primary PCI 0.43 (0.18-1.00) STEMI, Not Primary PCI 0.16 (0.03-0.80) 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 Odds Ratio 0.05 0.03 GIK better Placebo better
Median infarct size (IQR) Results: Biological Mechanism Cohort (N=153) 30-Day Infarct Size, LVEF, and Free Fatty Acid Levels 30-Day Infarct Size (% of LV mass) GIK Placebo 25 20 p=0.01 p=0.05 65 60 578 591 64 61 367 15 10 10 12 354 5 0 2 3 All ST Elevation
Page 1 and 2: Results of the IMMEDIATE (Immediate
Page 3 and 4: Carl Apstein, MD, FACC The IMMEDIAT
Page 5 and 6: Background: Rationale for Placebo-C
Page 7 and 8: Methods: Basic Features of Study De
Page 9 and 10: Methods: Pre-Specified Endpoints
Page 11 and 12: Methods: Exclusion Criteria • HF
Page 13 and 14: Methods: Analysis • Sample size c
Page 15 and 16: Results: Screening and Enrollment o
Page 17 and 18: Results: Time from Ischemic Symptom
Page 19 and 20: Results: ITT Cohort Hospital and 30
Page 21 and 22: Results: ITT Cohort Hospital and 30
Page 23 and 24: Results: Cohort Presenting with ST
Page 25: Results: Cohort Presenting with ST
Page 29 and 30: Median infarct size (IQR) Results:
Page 31 and 32: Limitations • Primary endpoint pr
Page 33 and 34: James Atkins • Assaad Sayah • M

Slides - Clinical Trial Results .org

Create successful ePaper yourself

Delete template?

Save as template?